A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD (BATTLE)

A Randomized Controlled Trial of Left Bundle brAnch opTimized Cardiac Resynchronization Therapy Versus conventionaL Bi-vEntricular Pacing in Heart Failure Patients With Nonspecific Intraventricular Conduction Delay

BATTLE study has been designed as a prospective, multi-center, randomized, controlled trial. This study will enroll 83 patients with chronic heart failure accompanied by intraventricular block (NICD) over an estimated recruitment period of 3 years. An LOT-CRT group will be compared with a group of conventional BiVP in the follow-up of at least 6 months. The study aimed to compare the curative effect of LOT-CRT in preserving LV systolic function with traditional BiVP in chronic heart failure patients with NICD.

Study Overview

Detailed Description

Cardiac resynchronization therapy is a standardized treatment strategy for patients with chronic heart failure complicated by wide QRS waves. With the continuous development of physiological pacing technology, traditional cardiac resynchronization therapy, namely biventricular pacing technology, is constantly challenged. Left bundle branch area pacing (LBBAP), as the main method of physiological pacing technology, is currently increasingly widely used in clinical practice. In recent years, research has mainly focused on heart failure patients with wide QRS waves such as non ischemic cardiomyopathy and typical left bundle branch block (LBBB). The recently published LBBP-RESYNC study was a randomized controlled study comparing left bundle branch pacing (LBBP) and biventricular pacing. The results showed that LBBP can achieve better improvement in left ventricular function compared to traditional biventricular pacing.

Compared with patients with typical LBBB, traditional biventricular pacing synchronized treatment is less effective in chronic heart failure patients accompanied by intraventricular block (NICD), which is closely related to the electrophysiological mechanism of LBBB. The blocking site of typical LBBB is generally located within the His bundle to the proximal end of the left bundle branch, while the distal end of the left bundle branch is relatively healthy. Therefore, LBBP can completely correct this type of LBBB and significantly narrow the QRS wave; The electrophysiological mechanism of NICD is relatively complex, and there may be multiple blocking sites, and LBBP cannot be completely corrected. How to improve the treatment efficacy and clinical prognosis of chronic heart failure patients with NICD is an important scientific issue that urgently needs to be solved. It is unclear whether left bundle branch pacing technology can provide support for cardiac function in such patients.

Traditional biventricular pacing combines right ventricular and left epicardial pacing; LBBAP combined with left ventricular epicardial pacing, also known as LOT-CRT, is an innovative pacing method. This study aims to explore the application value of LBBAP in patients with chronic heart failure and NICD.

Study Type

Interventional

Enrollment (Estimated)

86

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • The First Affiliated Hospital with Nanjing Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Ischemic or non ischemic cardiomyopathy
  2. Optimal medical therapy for at lest 3 months
  3. NYHA class II-IV
  4. LVEF≤35% as assessed by echocardiography
  5. Sinus rhythm (may have paroxysmal atrial fibrillation)
  6. QRS duration ≥ 150ms
  7. Intraventricular block (NICD), QRS morphology is neither LBBB nor RBBB

Exclusion Criteria:

  1. Valvular heart disease that requires or has undergone surgical intervention
  2. After mechanical tricuspid valve replacement
  3. Persistent or permanent atrial fibrillation or atrial flutter
  4. Second or third degree atrioventricular block
  5. Have a history of acute myocardial infarction within 3 months prior to enrollment
  6. Patient's expected survival time is less than 12 months
  7. Pregnant or planned to conceive
  8. Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole)
  9. Patients with simple and persistent left superior vena cava
  10. Patients with existing pacemaker implantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: LOT-CRT group

In this arm, an right artrial (RA) lead, an implantable cardioverter defibrillator (ICD) lead and a LV pacing lead are placed are conventionally implanted.

A left bundle branch pacing(LBBP) lead is attempted to be placed.

In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads

LBBAP includes LBBP and LVSP.

LBBP is defined if fulfilling criterion 1 and at least one in criteria 2:

  1. Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs);
  2. One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms:

    1. Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset;
    2. When reducing the output voltage, the LVAT undergoes a sudden change of>10ms;

If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP).

Active Comparator: BiVP group
In this arm, an RA lead , an ICD lead and a LV pacing lead are placed.
Implantation of a LV pacing lead is attempted using the standard-of-care technique first.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Left ventricular ejection fraction(LVEF)
Time Frame: Baseline; 6-month follow-up
Changes from baseline LVEF(unit: %) assessed by echocardiography at follow-up
Baseline; 6-month follow-up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Paced QRS duration
Time Frame: Postoperative day 1; 1-month,3-month and 6-month follow-up
Paced QRS duration is evaluated postoperative day 1 and 1 months, 3 months and 6 months after implantation.
Postoperative day 1; 1-month,3-month and 6-month follow-up
A combined clinical endpoint of all-cause mortality and heart failure hospitalization,
Time Frame: 6-month follow-up
Including date and number of all-cause mortalityand heart failure hospitalization,
6-month follow-up
Left ventricular end systolic volume(LVESV)
Time Frame: Baseline; 3-month, 6-month follow-up
Changes from baseline LVESV(unit: mL) assessed by echocardiography at follow-up
Baseline; 3-month, 6-month follow-up
Left ventricular end diastolic volume(LVEDV)
Time Frame: Baseline; 3-month, 6-month follow-up
Changes from baseline LVEDV(unit: mL) assessed by echocardiography at follow-up
Baseline; 3-month, 6-month follow-up
Left ventricular end systolic diameter(LVESD)
Time Frame: Baseline; 3-month, 6-month follow-up
Changes from baseline LVESD(unit: mm) assessed by echocardiography at follow-up
Baseline; 3-month, 6-month follow-up
Left ventricular end diastolic diameter(LVEDD)
Time Frame: Baseline; 3-month, 6-month follow-up
Changes from baseline LVEDD(unit: mm) assessed by echocardiography at follow-up
Baseline; 3-month, 6-month follow-up
Change in Quality Of Life Questionnaire score between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
Reflect the effect of cardiac funtion on quality of life, and higher scores represent a worse outcome
Baseline; 3-month, 6-month follow-up
Changes in New York Heart Association Heart Function Classification between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
The higher the classification, the more severe the heart failure symptoms(four levels: I, II, III and IV)
Baseline; 3-month, 6-month follow-up
Changes in 6-minute Walk Distance between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
Distance that a participant walk within 6 minutes
Baseline; 3-month, 6-month follow-up
Changes in concentration of NT-proBNP in blood between baseline and follow-up
Time Frame: Baseline; 3-month, 6-month follow-up
Blood test is performed at each time frame to determine the concentration of NT-proBNP(unit: pg/mL)
Baseline; 3-month, 6-month follow-up
Incidence of stroke events
Time Frame: 6-month follow-up
Including date and number of stroke
6-month follow-up
A combined arrhythmia endpoint of new-onset atrial fibrillation and malignant ventricular arrhythmia
Time Frame: 6-month follow-up
Including date and number of new-onset atrial fibrillation and malignant ventricular arrhythmia
6-month follow-up
Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation
Time Frame: Operative day
Success rate of LBBAP in LOT-CRT group
Operative day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 21, 2023

Primary Completion (Estimated)

March 1, 2027

Study Completion (Estimated)

March 1, 2027

Study Registration Dates

First Submitted

September 25, 2023

First Submitted That Met QC Criteria

September 25, 2023

First Posted (Actual)

September 29, 2023

Study Record Updates

Last Update Posted (Actual)

May 14, 2026

Last Update Submitted That Met QC Criteria

May 12, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FirstNanjingMU005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on LOT-CRT group

Subscribe